Dantrolene is neuroprotective in Huntington's disease transgenic mouse model

<p>Abstract</p> <p>Background</p> <p>Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a polyglutamine expansion in the Huntingtin protein which results in the selective degeneration of striatal medium spiny neurons (MSNs). Our group h...

Full description

Bibliographic Details
Main Authors: Chen Xi, Wu Jun, Lvovskaya Svetlana, Herndon Emily, Supnet Charlene, Bezprozvanny Ilya
Format: Article
Language:English
Published: BMC 2011-11-01
Series:Molecular Neurodegeneration
Subjects:
Online Access:http://www.molecularneurodegeneration.com/content/6/1/81
id doaj-2644779c04dd4e229a014427117da879
record_format Article
spelling doaj-2644779c04dd4e229a014427117da8792020-11-25T00:51:36ZengBMCMolecular Neurodegeneration1750-13262011-11-01618110.1186/1750-1326-6-81Dantrolene is neuroprotective in Huntington's disease transgenic mouse modelChen XiWu JunLvovskaya SvetlanaHerndon EmilySupnet CharleneBezprozvanny Ilya<p>Abstract</p> <p>Background</p> <p>Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a polyglutamine expansion in the Huntingtin protein which results in the selective degeneration of striatal medium spiny neurons (MSNs). Our group has previously demonstrated that calcium (Ca<sup>2+</sup>) signaling is abnormal in MSNs from the yeast artificial chromosome transgenic mouse model of HD (YAC128). Moreover, we demonstrated that deranged intracellular Ca<sup>2+ </sup>signaling sensitizes YAC128 MSNs to glutamate-induced excitotoxicity when compared to wild type (WT) MSNs. In previous studies we also observed abnormal neuronal Ca<sup>2+ </sup>signaling in neurons from spinocerebellar ataxia 2 (SCA2) and spinocerebellar ataxia 3 (SCA3) mouse models and demonstrated that treatment with dantrolene, a ryanodine receptor antagonist and clinically relevant Ca<sup>2+ </sup>signaling stabilizer, was neuroprotective in experiments with these mouse models. The aim of the current study was to evaluate potential beneficial effects of dantrolene in experiments with YAC128 HD mouse model.</p> <p>Results</p> <p>The application of caffeine and glutamate resulted in increased Ca<sup>2+ </sup>release from intracellular stores in YAC128 MSN cultures when compared to WT MSN cultures. Pre-treatment with dantrolene protected YAC128 MSNs from glutamate excitotoxicty, with an effective concentration of 100 nM and above. Feeding dantrolene (5 mg/kg) twice a week to YAC128 mice between 2 months and 11.5 months of age resulted in significantly improved performance in the beam-walking and gait-walking assays. Neuropathological analysis revealed that long-term dantrolene feeding to YAC128 mice significantly reduced the loss of NeuN-positive striatal neurons and reduced formation of Htt<sup>exp </sup>nuclear aggregates.</p> <p>Conclusions</p> <p>Our results support the hypothesis that deranged Ca<sup>2+ </sup>signaling plays an important role in HD pathology. Our data also implicate the RyanRs as a potential therapeutic target for the treatment of HD and demonstrate that RyanR inhibitors and Ca<sup>2+ </sup>signaling stabilizers such as dantrolene should be considered as potential therapeutics for the treatment of HD and other polyQ-expansion disorders.</p> http://www.molecularneurodegeneration.com/content/6/1/81Huntington's diseasecalcium signalingcalcium imagingcell deathdantroleneryanodine receptoraggregationneuroprotection
collection DOAJ
language English
format Article
sources DOAJ
author Chen Xi
Wu Jun
Lvovskaya Svetlana
Herndon Emily
Supnet Charlene
Bezprozvanny Ilya
spellingShingle Chen Xi
Wu Jun
Lvovskaya Svetlana
Herndon Emily
Supnet Charlene
Bezprozvanny Ilya
Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
Molecular Neurodegeneration
Huntington's disease
calcium signaling
calcium imaging
cell death
dantrolene
ryanodine receptor
aggregation
neuroprotection
author_facet Chen Xi
Wu Jun
Lvovskaya Svetlana
Herndon Emily
Supnet Charlene
Bezprozvanny Ilya
author_sort Chen Xi
title Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
title_short Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
title_full Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
title_fullStr Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
title_full_unstemmed Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
title_sort dantrolene is neuroprotective in huntington's disease transgenic mouse model
publisher BMC
series Molecular Neurodegeneration
issn 1750-1326
publishDate 2011-11-01
description <p>Abstract</p> <p>Background</p> <p>Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a polyglutamine expansion in the Huntingtin protein which results in the selective degeneration of striatal medium spiny neurons (MSNs). Our group has previously demonstrated that calcium (Ca<sup>2+</sup>) signaling is abnormal in MSNs from the yeast artificial chromosome transgenic mouse model of HD (YAC128). Moreover, we demonstrated that deranged intracellular Ca<sup>2+ </sup>signaling sensitizes YAC128 MSNs to glutamate-induced excitotoxicity when compared to wild type (WT) MSNs. In previous studies we also observed abnormal neuronal Ca<sup>2+ </sup>signaling in neurons from spinocerebellar ataxia 2 (SCA2) and spinocerebellar ataxia 3 (SCA3) mouse models and demonstrated that treatment with dantrolene, a ryanodine receptor antagonist and clinically relevant Ca<sup>2+ </sup>signaling stabilizer, was neuroprotective in experiments with these mouse models. The aim of the current study was to evaluate potential beneficial effects of dantrolene in experiments with YAC128 HD mouse model.</p> <p>Results</p> <p>The application of caffeine and glutamate resulted in increased Ca<sup>2+ </sup>release from intracellular stores in YAC128 MSN cultures when compared to WT MSN cultures. Pre-treatment with dantrolene protected YAC128 MSNs from glutamate excitotoxicty, with an effective concentration of 100 nM and above. Feeding dantrolene (5 mg/kg) twice a week to YAC128 mice between 2 months and 11.5 months of age resulted in significantly improved performance in the beam-walking and gait-walking assays. Neuropathological analysis revealed that long-term dantrolene feeding to YAC128 mice significantly reduced the loss of NeuN-positive striatal neurons and reduced formation of Htt<sup>exp </sup>nuclear aggregates.</p> <p>Conclusions</p> <p>Our results support the hypothesis that deranged Ca<sup>2+ </sup>signaling plays an important role in HD pathology. Our data also implicate the RyanRs as a potential therapeutic target for the treatment of HD and demonstrate that RyanR inhibitors and Ca<sup>2+ </sup>signaling stabilizers such as dantrolene should be considered as potential therapeutics for the treatment of HD and other polyQ-expansion disorders.</p>
topic Huntington's disease
calcium signaling
calcium imaging
cell death
dantrolene
ryanodine receptor
aggregation
neuroprotection
url http://www.molecularneurodegeneration.com/content/6/1/81
work_keys_str_mv AT chenxi dantroleneisneuroprotectiveinhuntingtonsdiseasetransgenicmousemodel
AT wujun dantroleneisneuroprotectiveinhuntingtonsdiseasetransgenicmousemodel
AT lvovskayasvetlana dantroleneisneuroprotectiveinhuntingtonsdiseasetransgenicmousemodel
AT herndonemily dantroleneisneuroprotectiveinhuntingtonsdiseasetransgenicmousemodel
AT supnetcharlene dantroleneisneuroprotectiveinhuntingtonsdiseasetransgenicmousemodel
AT bezprozvannyilya dantroleneisneuroprotectiveinhuntingtonsdiseasetransgenicmousemodel
_version_ 1725244938192420864